Butylscopolamine

DB09300

small molecule approved investigational vet_approved

Deskripsi

Butylscopolamine is a peripherally acting antimuscarinic, anticholinergic agent. It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms. It is not a pain medication in the normal sense, since it does not directly affect pain, but rather works to prevent painful cramps and spasms from occurring. It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system.

Struktur Molekul 2D

Berat 360.473
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The half life of elimination is 1-5 hours [A7905].
Volume Distribusi The volume of distribution is 128 liters [A7905].
Klirens (Clearance) Total clearace is 1.2 liters per minute [A7905].

Absorpsi

Scopolamine butylbromide has extremely low oral bioavailability with only 0.25-0.82% reaching systemic circulation A7905. Peak plasma concentration is reached 0.25-2 hours. Scopolamine butylbromide does not cross the blood brain barrier.

Metabolisme

Metabolism occurs mainly through hydrolysis of the ester bond A7905. The metabolites are not considered to be significantly active.

Rute Eliminasi

Mainly eliminated in the feces (69.7%) with very little in the urine (4.4%) A7905. Only 2.8% is eliminated via the bile owing to scopolamine butylbromide's poor absorption.

Interaksi Obat

516 Data
Aclidinium The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Aclidinium.
Mianserin Mianserin may increase the anticholinergic activities of Butylscopolamine.
Mirabegron The risk or severity of urinary retention can be increased when Butylscopolamine is combined with Mirabegron.
Potassium chloride The risk or severity of gastrointestinal ulceration can be increased when Butylscopolamine is combined with Potassium chloride.
Pramlintide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Butylscopolamine.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Butylscopolamine.
Tiotropium The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Tiotropium.
Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Butylscopolamine is combined with Topiramate.
Umeclidinium The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Umeclidinium.
Glycopyrronium The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Glycopyrronium.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Botulinum toxin type A.
Glucagon Butylscopolamine may increase the gastrointestinal motility reducing activities of Glucagon.
Sulpiride Butylscopolamine may increase the anticholinergic activities of Sulpiride.
Botulinum toxin type B The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Botulinum toxin type B.
Eluxadoline The risk or severity of constipation can be increased when Butylscopolamine is combined with Eluxadoline.
Ramosetron The risk or severity of constipation can be increased when Butylscopolamine is combined with Ramosetron.
Naltrexone The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Naltrexone.
Bezitramide The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Bezitramide.
Tramadol The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Tramadol.
Morphine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Morphine.
Codeine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Codeine.
Hydromorphone The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Hydromorphone.
Methadone The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Methadone.
Meperidine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Meperidine.
Oxycodone The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Oxycodone.
Butorphanol The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Butorphanol.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Dextropropoxyphene.
Pentazocine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Pentazocine.
Sufentanil The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Sufentanil.
Alfentanil The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Alfentanil.
Fentanyl The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Fentanyl.
Nalbuphine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Nalbuphine.
Levorphanol The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Levorphanol.
Remifentanil The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Remifentanil.
Buprenorphine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Buprenorphine.
Hydrocodone The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Hydrocodone.
Diphenoxylate The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Diphenoxylate.
Oxymorphone The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Oxymorphone.
Dezocine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Dezocine.
Levacetylmethadol The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Levacetylmethadol.
Methadyl acetate The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Dihydroetorphine.
Diamorphine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Diamorphine.
Ethylmorphine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Ethylmorphine.
Etorphine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Dextromoramide.
Desomorphine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Desomorphine.
Carfentanil The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Carfentanil.
Dihydrocodeine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Dihydromorphine.
Tapentadol The risk or severity of urinary retention and constipation can be increased when Butylscopolamine is combined with Tapentadol.
Ketobemidone The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Ketobemidone.
DPDPE The risk or severity of adverse effects can be increased when Butylscopolamine is combined with DPDPE.
Lofentanil The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Lofentanil.
Opium The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Opium.
Normethadone The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Normethadone.
Piritramide The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Piritramide.
Alphaprodine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Alphaprodine.
Nicomorphine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Nicomorphine.
Meptazinol The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Meptazinol.
Phenoperidine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Phenoperidine.
Phenazocine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Phenazocine.
Tilidine The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Tilidine.
Carfentanil, C-11 The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Carfentanil, C-11.
Benzhydrocodone The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Benzhydrocodone.
Naloxegol The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Naloxegol.
Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Butylscopolamine.
Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Butylscopolamine.
Benzatropine The risk or severity of adverse effects can be increased when Benzatropine is combined with Butylscopolamine.
Disopyramide The risk or severity of adverse effects can be increased when Disopyramide is combined with Butylscopolamine.
Metixene The risk or severity of adverse effects can be increased when Metixene is combined with Butylscopolamine.
Terfenadine The risk or severity of adverse effects can be increased when Terfenadine is combined with Butylscopolamine.
Buclizine The risk or severity of adverse effects can be increased when Buclizine is combined with Butylscopolamine.
Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Butylscopolamine.
Oxyphencyclimine The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Butylscopolamine.
Procyclidine The risk or severity of adverse effects can be increased when Procyclidine is combined with Butylscopolamine.
Hyoscyamine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Butylscopolamine.
Methscopolamine bromide The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Butylscopolamine.
Darifenacin The risk or severity of adverse effects can be increased when Darifenacin is combined with Butylscopolamine.
Tridihexethyl The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Butylscopolamine.
Anisotropine methylbromide The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Butylscopolamine.
Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Butylscopolamine.
Nicardipine The risk or severity of adverse effects can be increased when Nicardipine is combined with Butylscopolamine.
Mecamylamine The risk or severity of adverse effects can be increased when Mecamylamine is combined with Butylscopolamine.
Pirenzepine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Butylscopolamine.
Homatropine methylbromide The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Butylscopolamine.
Benzquinamide The risk or severity of adverse effects can be increased when Benzquinamide is combined with Butylscopolamine.
Propantheline The risk or severity of adverse effects can be increased when Propantheline is combined with Butylscopolamine.
Dicyclomine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Butylscopolamine.
Tropicamide The risk or severity of adverse effects can be increased when Tropicamide is combined with Butylscopolamine.
Cocaine The risk or severity of adverse effects can be increased when Cocaine is combined with Butylscopolamine.
Quinidine The risk or severity of adverse effects can be increased when Quinidine is combined with Butylscopolamine.
Amantadine The risk or severity of adverse effects can be increased when Amantadine is combined with Butylscopolamine.
Methantheline The risk or severity of adverse effects can be increased when Methantheline is combined with Butylscopolamine.
Cycrimine The risk or severity of adverse effects can be increased when Cycrimine is combined with Butylscopolamine.
Cyclopentolate The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Butylscopolamine.
Tolterodine The risk or severity of adverse effects can be increased when Tolterodine is combined with Butylscopolamine.
Oxybutynin The risk or severity of adverse effects can be increased when Oxybutynin is combined with Butylscopolamine.
Pentolinium The risk or severity of adverse effects can be increased when Pentolinium is combined with Butylscopolamine.

Target Protein

Muscarinic acetylcholine receptor M3 CHRM3
Muscarinic acetylcholine receptor M5 CHRM5
Muscarinic acetylcholine receptor M2 CHRM2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 17547475
    Tytgat GN: Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs. 2007;67(9):1343-57.

Contoh Produk & Brand

Produk: 6 • International brands: 0
Produk
  • Accel-hyoscine
    Tablet • 10 mg • Oral • Canada • Generic • Approved
  • Buscopan
    Tablet • 10 mg • Oral • Canada • Approved
  • Buscopan
    Solution • 20 mg / mL • Intramuscular; Intravenous; Subcutaneous • Canada • Approved
  • Buscopan Sup 10mg
    Suppository • 10 mg / sup • Rectal • Canada • Approved
  • Hyoscine Butylbromide Injection
    Solution • 20 mg / mL • Intramuscular; Intravenous; Subcutaneous • Canada • Approved
  • Hyoscine Butylbromide Injection BP
    Solution • 20 mg / mL • Intramuscular; Intravenous; Subcutaneous • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul